1. |
- Bigal, Marcelo E, et al.
(författare)
-
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
- 2015
-
Ingår i: Lancet Neurology. - 1474-4465. ; 14:11, s. 1091-1100
-
Tidskriftsartikel (refereegranskat)abstract
- Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.
|
|